Cigarette smoking in Parkinson's disease: influence on disease progression.
Identifieur interne : 003524 ( PubMed/Checkpoint ); précédent : 003523; suivant : 003525Cigarette smoking in Parkinson's disease: influence on disease progression.
Auteurs : Guido Alves [Norvège] ; Martin Kurz ; Stein A. Lie ; Jan P. LarsenSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Cognition Disorders (diagnosis), Cognition Disorders (epidemiology), Cross-Sectional Studies, Disease Progression, Female, Follow-Up Studies, Humans, Male, Nicotine (administration & dosage), Nicotine (pharmacology), Parkinson Disease (diagnosis), Parkinson Disease (epidemiology), Prevalence, Prospective Studies, Questionnaires, Severity of Illness Index, Smoking (epidemiology), Substantia Nigra (drug effects), Substantia Nigra (pathology), Tobacco Use Disorder (epidemiology).
- MESH :
- chemical , administration & dosage : Nicotine.
- diagnosis : Cognition Disorders, Parkinson Disease.
- drug effects : Substantia Nigra.
- epidemiology : Cognition Disorders, Parkinson Disease, Smoking, Tobacco Use Disorder.
- pathology : Substantia Nigra.
- chemical , pharmacology : Nicotine.
- Aged, Aged, 80 and over, Cross-Sectional Studies, Disease Progression, Female, Follow-Up Studies, Humans, Male, Prevalence, Prospective Studies, Questionnaires, Severity of Illness Index.
Abstract
Previous studies have shown an inverse association between smoking and the prevalence of Parkinson's disease (PD), suggesting that smoking may induce a biological protection against nigral neuronal damage. In 1993, we examined the frequency of cigarette smokers among 239 patients with PD and two control groups. In addition, the progression of parkinsonism and other clinical features were followed prospectively in smoking and nonsmoking PD patients over an 8-year period. Mortality in the two PD groups was also examined. We found a 50% higher prevalence of smokers in the control groups than in patients with PD. In contrast, during the follow-up period, there were no significant differences in progression of parkinsonism, cognitive impairment, and mood in smoking and nonsmoking patients with PD. Mortality was also similar in the two groups. The lack of influence on disease progression may indicate that cigarette smoking does not have a major neuroprotective effect in patients with already diagnosed PD.
DOI: 10.1002/mds.20117
PubMed: 15372603
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15372603Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cigarette smoking in Parkinson's disease: influence on disease progression.</title><author><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neurology, Central Hospital of Rogaland, Stavanger</wicri:regionArea><wicri:noRegion>Stavanger</wicri:noRegion></affiliation></author><author><name sortKey="Kurz, Martin" sort="Kurz, Martin" uniqKey="Kurz M" first="Martin" last="Kurz">Martin Kurz</name></author><author><name sortKey="Lie, Stein A" sort="Lie, Stein A" uniqKey="Lie S" first="Stein A" last="Lie">Stein A. Lie</name></author><author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P" last="Larsen">Jan P. Larsen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15372603</idno><idno type="pmid">15372603</idno><idno type="doi">10.1002/mds.20117</idno><idno type="wicri:Area/PubMed/Corpus">003348</idno><idno type="wicri:Area/PubMed/Curation">003348</idno><idno type="wicri:Area/PubMed/Checkpoint">003524</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cigarette smoking in Parkinson's disease: influence on disease progression.</title><author><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Neurology, Central Hospital of Rogaland, Stavanger</wicri:regionArea><wicri:noRegion>Stavanger</wicri:noRegion></affiliation></author><author><name sortKey="Kurz, Martin" sort="Kurz, Martin" uniqKey="Kurz M" first="Martin" last="Kurz">Martin Kurz</name></author><author><name sortKey="Lie, Stein A" sort="Lie, Stein A" uniqKey="Lie S" first="Stein A" last="Lie">Stein A. Lie</name></author><author><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P" last="Larsen">Jan P. Larsen</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cognition Disorders (diagnosis)</term><term>Cognition Disorders (epidemiology)</term><term>Cross-Sectional Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Nicotine (administration & dosage)</term><term>Nicotine (pharmacology)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (epidemiology)</term><term>Prevalence</term><term>Prospective Studies</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Smoking (epidemiology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (pathology)</term><term>Tobacco Use Disorder (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term><term>Smoking</term><term>Tobacco Use Disorder</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Substantia Nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nicotine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Sectional Studies</term><term>Disease Progression</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Prospective Studies</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous studies have shown an inverse association between smoking and the prevalence of Parkinson's disease (PD), suggesting that smoking may induce a biological protection against nigral neuronal damage. In 1993, we examined the frequency of cigarette smokers among 239 patients with PD and two control groups. In addition, the progression of parkinsonism and other clinical features were followed prospectively in smoking and nonsmoking PD patients over an 8-year period. Mortality in the two PD groups was also examined. We found a 50% higher prevalence of smokers in the control groups than in patients with PD. In contrast, during the follow-up period, there were no significant differences in progression of parkinsonism, cognitive impairment, and mood in smoking and nonsmoking patients with PD. Mortality was also similar in the two groups. The lack of influence on disease progression may indicate that cigarette smoking does not have a major neuroprotective effect in patients with already diagnosed PD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15372603</PMID><DateCreated><Year>2004</Year><Month>09</Month><Day>16</Day></DateCreated><DateCompleted><Year>2004</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2005</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Cigarette smoking in Parkinson's disease: influence on disease progression.</ArticleTitle><Pagination><MedlinePgn>1087-1092</MedlinePgn></Pagination><Abstract><AbstractText>Previous studies have shown an inverse association between smoking and the prevalence of Parkinson's disease (PD), suggesting that smoking may induce a biological protection against nigral neuronal damage. In 1993, we examined the frequency of cigarette smokers among 239 patients with PD and two control groups. In addition, the progression of parkinsonism and other clinical features were followed prospectively in smoking and nonsmoking PD patients over an 8-year period. Mortality in the two PD groups was also examined. We found a 50% higher prevalence of smokers in the control groups than in patients with PD. In contrast, during the follow-up period, there were no significant differences in progression of parkinsonism, cognitive impairment, and mood in smoking and nonsmoking patients with PD. Mortality was also similar in the two groups. The lack of influence on disease progression may indicate that cigarette smoking does not have a major neuroprotective effect in patients with already diagnosed PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lie</LastName><ForeName>Stein A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Jan P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>54-11-5</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2005 May;20(5):641-2</RefSource><PMID Version="1">15747366</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003072">Cognition Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003430">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012907">Smoking</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014029">Tobacco Use Disorder</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15372603</ArticleId><ArticleId IdType="doi">10.1002/mds.20117</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Norvège</li></country></list><tree><noCountry><name sortKey="Kurz, Martin" sort="Kurz, Martin" uniqKey="Kurz M" first="Martin" last="Kurz">Martin Kurz</name><name sortKey="Larsen, Jan P" sort="Larsen, Jan P" uniqKey="Larsen J" first="Jan P" last="Larsen">Jan P. Larsen</name><name sortKey="Lie, Stein A" sort="Lie, Stein A" uniqKey="Lie S" first="Stein A" last="Lie">Stein A. Lie</name></noCountry><country name="Norvège"><noRegion><name sortKey="Alves, Guido" sort="Alves, Guido" uniqKey="Alves G" first="Guido" last="Alves">Guido Alves</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003524 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003524 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15372603
|texte= Cigarette smoking in Parkinson's disease: influence on disease progression.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15372603" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |